Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | DGKA | P23743 | 1/20 | 0.54 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.54 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triacetin SCHEMBL9300248 | 0.95 | PRKCA (0.69) | PRKCAALDH1A1LMNAMAPTDGKA | |
| SCHEMBL1477766 | 0.91 | PRKCA (0.80) | PRKCAALDH1A1LMNAMAPTPRKCE | |
| SCHEMBL383519 | 0.91 | PRKCA (0.80) | PRKCAALDH1A1LMNAMAPTPRKCE | |
| SCHEMBL385116 | 0.91 | PRKCA (0.80) | PRKCAALDH1A1LMNAMAPTPRKCE | |
| SCHEMBL207207 | 0.91 | PRKCA (0.80) | PRKCAALDH1A1LMNAMAPTPRKCE | |
| SCHEMBL385481 | 0.91 | PRKCA (0.80) | PRKCAALDH1A1LMNAMAPTPRKCE | |
| SCHEMBL11995515 | 0.91 | PRKCA (0.80) | PRKCAALDH1A1LMNAMAPTPRKCE | |
| SCHEMBL385978 | 0.91 | PRKCA (0.80) | PRKCAALDH1A1LMNAMAPTPRKCE | |
| SCHEMBL386248 | 0.91 | PRKCA (0.80) | PRKCAALDH1A1LMNAMAPTPRKCE | |
| SCHEMBL385995 | 0.91 | PRKCA (0.80) | PRKCAALDH1A1LMNAMAPTPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709855-A2 | SINGLE-STRANDED LOOP OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250304957-A1 | SINGLE-STRANDED LOOP OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2025-10-02 | — | — | US | disclosed |
| US-20250270562-A1 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | BANK OF AMERICA, N.A. | 2025-08-28 | — | — | US | disclosed |
| US-12397013-B2 | Extrahepatic delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4594492-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4547683-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | Alnylam Pharmaceuticals, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025064660-A2 | ACTIVIN A RECEPTOR TYPE 1C (ACVR1C) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| EP-4522742-A2 | SINGLE-STRANDED LOOP OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2024238385-A2 | SINGLE-STRANDED LOOP OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240360455-A1 | EXTRA-HEPATIC DELIVERY IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-10-31 | — | — | US | disclosed |
| EP-1605978-A2 | THERAPEUTIC COMPOSITIONS | Alnylam Pharmaceuticals Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050153337-A1 | iRNA conjugates | ALNYLAM PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2004094595-A2 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004091515-A2 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004090108-A2 | IRNA CONJUGATES | ALNYLAM PHARMACEUTICALS (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004080406-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004064737-A2 | THERAPEUTICS COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004030634-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153337-A1 | iRNA conjugates | AGO2, NSUN3, RNASE1 | PRKCA 4483/4885ALDH1A1 2957/4885LMNA 466/4885 |
| US-20240360455-A1 | EXTRA-HEPATIC DELIVERY IRNA COMPOSITIONS AND METHODS OF USE THEREOF | TNNC1, CPT1B, TNNI3 | PRKCA 2367/4885ALDH1A1 3262/4885LMNA 136/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | PRKCA 3722/4885ALDH1A1 1587/4885LMNA 295/4885 |
| US-12397013-B2 | Extrahepatic delivery | RNASE1, LDLR, HAVCR2 | PRKCA 4553/4885ALDH1A1 1420/4885LMNA 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.